St. Justine's Hospital   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Montreal Canada (1907)

Organization Overview

First Clinical Trial
2006
NCT00757874
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Ahmed Moussa | Deana Funaro | Evelyne D.Trottier | Ibrahim Mohamed | Jantchou Prevost | Michael Marchand, MD | Philippe Bégin | Research Centre IUSMM | St. Justine's Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 3)

Asthma (Phase 3)

Bronchiolitis (Phase 3)

Cholestasis (Phase 3)

Chromosome Aberrations (Phase 2)

Chromosome Disorders (Phase 2)

Conjunctivitis (Phase 4)

Conjunctivitis, Allergic (Phase 4)

Crohn Disease (Phase 3)

Fragile X Syndrome (Phase 2)

Genetic Diseases, Inborn (Phase 2)

Genetic Diseases, X-Linked (Phase 2)

Glioma (Phase 2)

Hypersensitivity (Phase 2)

Intellectual Disability (Phase 2)

Lacerations (Phase 2)

Lichen Sclerosus et Atrophicus (Phase 2)

Mental Retardation, X-Linked (Phase 2)

Neurobehavioral Manifestations (Phase 2)

Neurofibroma (Phase 2)

Neurofibroma, Plexiform (Phase 2)

Neurofibromatoses (Phase 2)

Sex Chromosome Disorders (Phase 2)

Syndrome (Phase 2)

Vulvar Lichen Sclerosus (Phase 2)

Whooping Cough (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial APIs: 28